REFERENCES
1. Ho GJK, Tan FXN, Sasikumar NA, et al. High global prevalence of steatotic liver disease and associated subtypes: a meta-analysis. Clin Gastroenterol Hepatol. 2025;23:2423-32.e1.
2. Younossi ZM, Golabi P, Price JK, et al. The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2024;22:1999-2010.e8.
3. Lee BP, Dodge JL, Terrault NA. National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature. Hepatology. 2024;79:666-73.
4. Kalligeros M, Vassilopoulos A, Vassilopoulos S, Victor DW, Mylonakis E, Noureddin M. Prevalence of steatotic liver disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020. Clin Gastroenterol Hepatol. 2024;22:1330-2.e4.
5. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797-835.
6. Rinella ME, Lazarus JV, Ratziu V, et al.; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966-86.
7. Gao B, Arab JP, Liangpunsakul S, et al. Metabolic dysfunction and alcohol-associated liver disease (MetALD). eGastroenterology. 2025;3:e100319.
8. Yeoh A, Yang Z, Cheung R, Do A, Ahmed A, Wong RJ. Incidence of cirrhosis and hepatocellular carcinoma among veterans with noncirrhotic metabolic dysfunction-associated fatty liver disease. J Clin Gastroenterol. 2024;58:718-25.
9. Wong RJ, Yang Z, Cheung R, et al. Impact of longitudinal alcohol use patterns on long-term risk of cirrhosis among US veterans with steatotic liver disease. Gastroenterology. 2024;166:1156-65.e4.
10. Rivera-Esteban J, Muñoz-Martínez S, Higuera M, et al. Phenotypes of metabolic dysfunction-associated steatotic liver disease-associated hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2024;22:1774-89.e8.
11. Chen YT, Chen TI, Yang TH, et al. Long-term risks of cirrhosis and hepatocellular carcinoma across steatotic liver disease subtypes. Am J Gastroenterol. 2024;119:2241-50.
12. Chen L, Tao X, Zeng M, Mi Y, Xu L. Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD. J Hepatol. 2024;80:e64-6.
13. Wu T, Ye J, Mo S, et al. Impact of nomenclature as metabolic associated steatotic liver disease on steatotic liver disease prevalence and screening: a prospective population survey in Asians. J Gastroenterol Hepatol. 2024;39:1636-47.
14. Miwa T, Tajirika S, Imamura N, et al. Prevalence of steatotic liver disease based on a new nomenclature in the japanese population: a health checkup-based cross-sectional study. J Clin Med. 2024;13:1158.
15. Mori K, Akiyama Y, Tanaka M, et al. Deciphering metabolic dysfunction-associated steatotic liver disease: insights from predictive modeling and clustering analysis. J Gastroenterol Hepatol. 2024;39:1382-93.
16. Park HJ, Lee S, Lee JS. Differences in the prevalence of NAFLD, MAFLD, and MASLD according to changes in the nomenclature in a health check-up using MRI-derived proton density fat fraction. Abdom Radiol. 2024;49:3036-44.
17. Lee CM, Yoon EL, Kim M, et al. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings. Hepatology. 2024;79:1393-400.
18. Choe HJ, Moon JH, Kim W, Koo BK, Cho NH. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: a community-dwelling cohort study with 20-year follow-up. Metabolism. 2024;153:155800.
19. Tamaki N, Kimura T, Wakabayashi SI, et al. Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality. Aliment Pharmacol Ther. 2024;60:61-9.
20. Kim A, Kang D, Choi SC, Cho J, Sinn DH, Gwak GY. Steatotic liver disease and its newly proposed sub-classifications correlate with progression of the coronary artery calcium score. PLoS ONE. 2024;19:e0301126.
21. Lee HH, Lee HA, Kim EJ, et al. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Gut. 2024;73:533-40.
22. Wong RJ, Yang Z, Sedki M, Zhang W, Singal AK, Cheung R. Estimating steatotic liver disease prevalence among US veterans. Gastro Hep Adv. 2025;4:100804.
23. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335-47.
24. Paik JM, Hobbs K, Gupta A, Alkalbani RJ, Reyes MA, Younossi ZM. Prevalence of MASLD, Met-ALD, and ALD and associated fibrosis among US adults: insights from NHANES 2017 to 2023. J Clin Gastroenterol. 2025;Epub ahead of print.
25. Krag A, Torp N, Younossi ZM, Israelsen M. Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD. Lancet Gastroenterol Hepatol. 2025;10:282-4.
26. Marti-Aguado D, Calleja JL, Vilar-Gomez E, et al. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2024;81:930-40.
27. Männistö V, Salomaa V, Jula A, et al. ALT levels, alcohol use, and metabolic risk factors have prognostic relevance for liver-related outcomes in the general population. JHEP Rep. 2024;6:101172.
28. Israelsen M, Thorhauge KH, Andersen P, et al. Steatotic liver disease classification is dynamic, affecting clinical trial eligibility and subclass-specific treatments. Clin Gastroenterol Hepatol. 2025;23:2509-18.
29. Sedki M, Yang Z, Singal AK, et al. Longitudinal risk of cirrhosis by steatotic liver disease subtype among 1.5 million individuals in the US. JHEP Rep. ;8:101680.
30. Sripongpun P, Kaewdech A, Udompap P, Kim WR. Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score. JHEP Rep. 2024;6:101127.
31. Tampaki M, Tsochatzis E, Lekakis V, Cholongitas E. Prevalence, characteristics and outcomes of patients with metabolic and alcohol related/associated liver disease (MetALD): a systematic review and meta-analysis. Metabolism. 2025;163:156101.
32. Celletti F, Farrar J, De Regil L. World health organization guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults. JAMA. 2026;335:434-8.
33. Alfaris N, Waldrop S, Johnson V, Boaventura B, Kendrick K, Stanford FC. GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review. EClinicalMedicine. 2024;75:102782.
34. Sanyal AJ, Newsome PN, Kliers I, et al.; ESSENCE Study Group. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392:2089-99.
35. Hendershot CS, Bremmer MP, Paladino MB, et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2025;82:395-405.
